- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022;40(10):1051-1058.
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11-18.
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: The randomized clinical FinXX trial. JAMA Oncol. 2017;3(6):793-800.
Findings
What does this study add?
- Overall survival at 15 years was significantly longer in the capecitabine-treated group (77.6% for TX-CEX) than in the control group (73.3% for T-CEF) (HR 0.81; 95% CI, 0.66 to 0.99; log-rank test p=0.037; Gehan-Breslow-Wilcoxon test p=0.044) (Figure 1).
- Evaluation of stratification factors for exploratory subgroup survival analyses showed that patients with ER-negative cancer and HER2-negative cancer tended to live longer when treated with TX-CEX compared to those treated with T-CEF, and patients with triple-negative cancer (ER-negative, HER2-negative, and progesterone-receptor (PR)-negative) also tended to live longer with TX-CEX compared to the other subgroups but these difference between the subgroups were not significant (Figure 2).
